The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
- DOI
- 10.1007/s10549-008-0183-2
- Published
- 2009 Jul
- Container
- Breast cancer research and treatment
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-008-0183-2,
title = {The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.},
author = {Zhang Y and Sieuwerts AM and McGreevy M and Casey G and Cufer T and Paradiso A and Harbeck N and Span PN and Hicks DG and Crowe J and Tubbs RR and Budd GT and Lyons J and Sweep FC and Schmitt M and Schittulli F and Golouh R and Talantov D and Wang Y and Foekens JA},
year = {2009},
journal = {Breast cancer research and treatment},
doi = {10.1007/s10549-008-0183-2},
url = {https://doi.org/10.1007/s10549-008-0183-2}
}RIS
TY - JOUR TI - The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. AU - Zhang Y AU - Sieuwerts AM AU - McGreevy M AU - Casey G AU - Cufer T AU - Paradiso A AU - Harbeck N AU - Span PN AU - Hicks DG AU - Crowe J AU - Tubbs RR AU - Budd GT AU - Lyons J AU - Sweep FC AU - Schmitt M AU - Schittulli F AU - Golouh R AU - Talantov D AU - Wang Y AU - Foekens JA PY - 2009 JO - Breast cancer research and treatment DO - 10.1007/s10549-008-0183-2 UR - https://doi.org/10.1007/s10549-008-0183-2 ER -
APA
Y, Z., AM, S., M, M., G, C., T, C., A, P., N, H., PN, S., DG, H., J, C., RR, T., GT, B., J, L., FC, S., M, S., F, S., R, G., D, T., Y, W., & JA, F. (2009). The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-008-0183-2
Source records
- pubmed · retrieved 2026-09-25T06:25:37.950Z